Experienced in Acid Sphingomyelinase Deficiency (ASMD)

Maria J. Molnar

Mária Str. 39, 
Budapest, BU, HU 
Experienced in Acid Sphingomyelinase Deficiency (ASMD)
Mária Str. 39, 
Budapest, BU, HU 
OverviewLocationsClinical Research

Overview

Maria Molnar practices in Budapest, Hungary. Ms. Molnar is rated as an Experienced expert by MediFind in the treatment of Acid Sphingomyelinase Deficiency (ASMD). Her top areas of expertise are Hallervorden-Spatz Disease, Drug Induced Dyskinesia, Chorea, Primary Lateral Sclerosis, and Thalamotomy.

Her clinical research consists of co-authoring 99 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Acid Sphingomyelinase Deficiency (ASMD).

Gender
Female

Locations

Mária Str. 39, Budapest, BU 1085, Hungary
Other Locations
26 Üllői Rd, Budapest, BU 1085, Hungary
Tomo Street 25-29, Budapest, BU 1083, Hungary

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy
A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy
Enrollment Status: Completed
Publish Date: May 08, 2024
Intervention Type: Drug
Study Drug: REN001
Study Phase: Phase 2
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drugs: PRX-102 (Pegunigalsidase Alfa), Agalsidase Beta
Study Phase: Phase 3
View 2 Less Clinical Trials

97 Total Publications

Results of the Hungarian Newborn Screening Pilot Program for Spinal Muscular Atrophy.
Results of the Hungarian Newborn Screening Pilot Program for Spinal Muscular Atrophy.
Journal: International journal of neonatal screening
Published: February 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Molnar's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 67 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile